ClinicalTrials.gg
TerminatedNCT02710279SADS-CSUpdated Aug 3, 2022

Response to Social Rejection in Suicidal Behavior

An interventional study of Trier Social Stress Test (TSST) and smartphone in Unipolar Depression, sponsored by University Hospital, Montpellier. Terminated at 1 site in France. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other

Why this study was terminated
difficulties in recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Suicide is a major health problem that causes annually a million death worldwild. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition and stressful condition. We hypothesized that the sensitivity to social exclusion may represent a core component of the suicidal vulnerability Recent evidence also suggest that inflammatory mediators plays a critical role in SB. Furthermore, social stressors are particulary strong and specific triggers of inflammatory response.

To sum up, patients carrying a suicidal vulnerability are expected to present greater responses to social rejection in terms of inflammatory activity and psychological pain.

The aim of the study is to evaluate the psychological and inflammatory responses to a social stressor validated, the Trier Social Stress Test (TSST) . We will also investigate the moderating effect of childhood abuse, attachment, trait rejection sensitivity and social isolation.

In the second part of the study, we will also investigate the prospective association between inflammatory responses induces by laboratory paradigms of social rejection and the occurrence of social distress, suicidal ideation and psychological pain in response to social exclusion events in real life (using ecological momentary assessment).

Read the detailed description

Over one year, we will recruit 140 female outpatients suffering from a major depressive episode with (n=70) and without any history of suicide attempt (n=70) from a specialized clinic for mood disorders and SB.

First visit: clinical, biological and neuropsychological assessment Second visit: The TSST is a standardized laboratory psychosocial stress protocol that involves public speaking, role play, and mental arithmetic tasks in front of a panel of confederate judges. Blood samples will be obtained before the introduction to the TSST and immediately after and at + 30, + 60, + 90, and + 120 min. Self-ratings of emotional states, anxiety, anger and psychological pain will be completed at the same times.

Third visit: Participants will be instructed to carry a smartphone with them for one week, and to record at each alarm signal daily life events, negative emotions, psychological pain, suicidal ideas, and specific attributions to these events. Participants will be signalled five times a day during the period. Subjects will be contacted by telephone halfway through the assessment period to monitor and encourage compliance.

02

Conditions studied

  • Unipolar Depression

Keywords

  • Psychiatry
  • Depressive disorder
  • Suicide
03

In context

Depressive Disorder

4,847 studies on the registry are indexed under Depressive Disorder; 509 are open to participants now.

This study's enrollment of 79 is close to the median of 80 across 3,997 interventional studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 227 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non specifics
  • Female
  • Between 18 and 65 years
  • Main diagnosis of unipolar major depressive episode (DSM-IV criteria)
  • Having signed informed consent
  • Able to understand nature, aims, and methodology oh the study
  • Specifics :
  • Having a personal history of suicidal behavior (group : depressed patient with history of SB) OR
  • Not Having personal history of suicidal behavior (group : depressed patient without history of SB)

Exclusion criteria

Exclusion criteria:

  • Inflammatory or intercurrent pathology
  • Lifetime history of schizophrenia, or schizoaffective or bipolar disorder, according to DSM-IV criteria;
  • Current diagnosis of substance abuse or dependence in the last year (excluding tobacco)
  • Current organic mental disorder or mental retardation, or severe comorbid medical condition
  • Participation in another clinical trial
  • Pregnancy
  • Not able to speak, read and understand French
  • Patient on protective measures (guardianship or trusteeship)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Other
    Depressive patients

    Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone

    Behavioral: Trier Social Stress Test (TSST) · Device: smartphone

Interventions

  • BehavioralTrier Social Stress Test (TSST)

    For the TSST the participants are instructed to imagine having applied for their "dream job" and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days.

  • Devicesmartphone
06

What researchers measure

Primary outcomes

  1. Psychological pain response to Trier Social Stress Test (TSST) assessed by visual analogic sale

    comparaison of psychological pain response between group with personal history of suicid attempt and group without personal history of suicid attempt

    Time frame: up to one week

Secondary outcomes

  1. Inflammatory response to TTST

    comparaison of blood markers of inflammation between groups

    Time frame: up to one week

  2. Impact of loneliness and childhood abuse on inflammatory markers

    comparaison of sacles scores (ESUL : loneliness scale and CTQ : childhood abuse scale) between groups on inflammatory markers

    Time frame: up to one week

  3. impact of neuropschychological function on psychological pain

    comparaison of neuropsychological tests between groups on psychological pain assessed by visual analogic scale

    Time frame: up to one week

  4. Social rejection assessed by likert scale in real life condition with a smartphone

    comparaison between groups whether inflammatory / psychological pain reactivity to a single experimental episode of social rejection in the laboratory relates to real-world social experience. It consists on self-assessments (with a smartphone) by Likert scales (feelings of social disconnection or rejection during their most recent social interaction, mood, negative affects, suicidal ideation, psychological pain), 5 times per day during 7 days

    Time frame: 7 days after the TSST

07

Study locations

1 site
  • University Hospital of Montpellier
    Montpellier, 34295, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Feb 2018, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2016
First posted
Mar 16, 2016
StartActual
Feb 19, 2016
Primary completionActual
Feb 15, 2018
CompletionActual
Feb 15, 2018
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02710279
Responsible party
Sponsor
First posted
Mar 16, 2016
Start date
Feb 19, 2016
Primary completion
Feb 15, 2018
Completion
Feb 15, 2018
Last update
Aug 3, 2022

Study contacts

Philippe Courtet, MD PhD
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion